-
Mashup Score: 0
The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 10RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9 - Genome Biology - 4 month(s) ago
Background The oncogenic protein HOXA9 plays a critical role in leukemia transformation and maintenance, and its aberrant expression is a hallmark of most aggressive acute leukemia. Although inhibiting the upstream regulators of HOXA9 has been proven as a significant therapeutic intervention, the comprehensive regulation network controlling HOXA9 expression in leukemia has not been systematically investigated. Results Here, we perform genome-wide CRISPR/Cas9 screening in the HOXA9-driven reporter acute leukemia cells. We identify a poorly characterized RNA-binding protein, RBM5, as the top candidate gene required to maintain leukemia cell fitness. RBM5 is highly overexpressed in acute myeloid leukemia (AML) patients compared to healthy individuals. RBM5 loss triggered by CRISPR knockout and shRNA knockdown significantly impairs leukemia maintenance in vitro and in vivo. Through domain CRISPR screening, we reveal that RBM5 functions through a noncanonical transcriptional regulation circ
Source: genomebiology.biomedcentral.comCategories: General Medicine News, General HCPsTweet-
HOXA9 tracking reveals RBM5 dual function and therapeutic potential for #acuteMyeloidLeukemia https://t.co/FDyAGK65sy https://t.co/SelRTDIAMI
-
-
Mashup Score: 5
Clinicians outline treatments for relapsed acute myeloid leukemia (AML), T-Cell activation, and more.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
Is ‘Inflamodulation’ What’s Missing From AML Immunotherapy? In this editorial, Jerald Radich, MD, of @fredhutch and Jacob Appelbaum, MD, PhD, of @UWDeptMedicine discuss treatments for relapsed #AcuteMyeloidLeukemia, T-Cell activation, and more. 📰 https://t.co/gPW2Hs6pol https://t.co/ptlTk7kOyZ
-
-
Mashup Score: 6
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands Amsterdam University Medical Centers,
Source: haematologica.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Measurable residual disease can guide treatment strategy in intermediate-risk #acuteMyeloidLeukemia patients: detailed analysis of the results of the HO132 trial. https://t.co/KJWp54v8nX https://t.co/jRwe7fcGVj
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Venetoclax plus azacitidine positively impacts health-related quality of life among #elderly patients with #acutemyeloidleukemia compared with azacitidine alone, according to findings from the #EHA2023 Hybrid Congress. https://t.co/dgxRtZSHJl #AML https://t.co/l1iASOKHJJ
-
-
Mashup Score: 0Gemtuzumab Ozogamicin Plus Intensive Chemotherapy Reduces Cumulative Incidence of Relapse Among Patients With NPM1-Mutated AML - 7 month(s) ago
The addition of gemtuzumab ozogamicin to intensive chemotherapy reduced the cumulative incidence of relapse among patients with newly diagnosed NPM1-mutated acute myeloid leukemia, according to findings from a phase 3 trial.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hartmut Döhner, MD, and coauthors stated, "the addition of #gemtuzumab #ozogamicin might reduce the need for salvage therapy in these participants." Learn more: https://t.co/wzvUXUjuvE #AML #AcuteMyeloidLeukemia #Leukemia #Oncology #OncologyNews https://t.co/Mj3WNdbOA8
-
-
Mashup Score: 0Vitamins C, D Supplementation Beneficial in Chemotherapy for Acute Myeloid Leukemia - 8 month(s) ago
Use of vitamin C and D supplementation evaluated for its efficacy for patients with AML undergoing intensive induction chemotherapy.
Source: www.oncologynurseadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Supplementation with vitamins C and D is both safe and beneficial for patients with #acuteMyeloidLeukemia who are undergoing chemotherapy. Published in @BloodAdvances. https://t.co/9ipnPbwJPw #AML
-
-
Mashup Score: 0The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia - 9 month(s) ago
The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives ris…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NOW ONLINE New Review discusses resistance mechanisms based on cell interactions and secreted soluble factors in the #HematopoieticNiche and provides an overview of niche-related therapeutic targets for #AcuteMyeloidLeukemia therapy 🔓OPEN ACCESS ➡️https://t.co/4qamEDG6cs https://t.co/WdA4b9vDwG
-
-
Mashup Score: 0
PURPOSE Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, non–favorable-risk AML. METHODS In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventiona
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧐 Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy was tolerable in patients with newly-diagnosed #AcuteMyeloidLeukemia ➡️ https://t.co/x6w5kyNKdn #AML #leusm https://t.co/Vs3hzdTJLm
-
-
Mashup Score: 0#ASCO23 - 10 month(s) ago
Catch up with our live Twitter coverage from the American Society of Clinical Oncology (#ASCO23) Annual Congress.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 #ASCO23 | In case you missed our live coverage from ASCO 2023, you can catch up below. 👉 https://t.co/fHKkT8DOIy #AMLHub #AMLsm #acutemyeloidleukemia @ASCO https://t.co/fIdH1YJRMV
-
This study may help explain why some patients with #AcuteMyeloidLeukemia (AML) are more prone to relapse following a complete response to induction therapy. Read here: https://t.co/FaBwdpj67m https://t.co/njfQTLaDKP